{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:26:27Z","timestamp":1791084387945,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41409-025-02639-6","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T07:36:05Z","timestamp":1750145765000},"page":"1249-1257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcome of second allogeneic hematopoietic cell transplantation in adult patients with relapsed B-cell acute lymphoblastic leukemia in the era of new immunotherapeutic agents"],"prefix":"10.1038","volume":"60","author":[{"given":"Daehun","family":"Kwag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9131","authenticated-orcid":false,"given":"Jae-Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gi June","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9810-2050","authenticated-orcid":false,"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-6616","authenticated-orcid":false,"given":"Byung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Seong","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4098-3366","authenticated-orcid":false,"given":"Hee-Je","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-4839","authenticated-orcid":false,"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-9814","authenticated-orcid":false,"given":"Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"2639_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/bmt.2012.195","volume":"48","author":"LM Poon","year":"2013","unstructured":"Poon LM, Bassett Jr R, Rondon G, Hamdi A, Qazilbash M, Hosing C, et al. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013;48:666\u201370.","journal-title":"Bone Marrow Transplant"},{"key":"2639_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3324\/haematol.2016.145631","volume":"102","author":"S Giebel","year":"2017","unstructured":"Giebel S, Labopin M, Soci\u00e9 G, Beelen D, Browne P, Volin L, et al. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:139\u201349.","journal-title":"Haematologica"},{"key":"2639_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-020-04310-0","volume":"100","author":"Y Mori","year":"2021","unstructured":"Mori Y, Sasaki K, Ito Y, Kuriyama T, Ueno T, Kadowaki M, et al. Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study. Ann Hematol. 2021;100:197\u2013208.","journal-title":"Ann Hematol"},{"key":"2639_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clml.2016.06.005","volume":"16","author":"MM Al Malki","year":"2016","unstructured":"Al Malki MM, Aldoss I, Stiller T, Nakamura R, Snyder DS, Forman SJ, et al. Outcome of second allogeneic hematopoietic cell transplantation in patients with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;16:519\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2639_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s12185-022-03377-x","volume":"116","author":"T Tachibana","year":"2022","unstructured":"Tachibana T, Tanaka M, Hagihara M, Fujimaki K, Kanamori H, Nakajima H. Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation. Int J Hematol. 2022;116:594\u2013602.","journal-title":"Int J Hematol"},{"key":"2639_CR6","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/s41409-021-01317-7","volume":"56","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Ciceri F, Finke J, Bruno B, et al. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant. 2021;56:2194\u2013202.","journal-title":"Bone Marrow Transplant"},{"key":"2639_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjh.15973","volume":"186","author":"A Nagler","year":"2019","unstructured":"Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019;186:767\u201376.","journal-title":"Br J Haematol"},{"key":"2639_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","volume":"29","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 2022;29:1080\u201396.","journal-title":"Cancer Gene Ther"},{"key":"2639_CR9","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","volume":"60","author":"H Rafei","year":"2019","unstructured":"Rafei H, Kantarjian HM, Jabbour EJ. Recent advances in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60:2606\u201321.","journal-title":"Leuk Lymphoma"},{"key":"2639_CR10","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018;5:e618\u2013e627.","journal-title":"Lancet Haematol"},{"key":"2639_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231154713","volume":"14","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Kwag D, Lee JH, Min GJ, Park SS, Park S, et al. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis. Ther Adv Hematol. 2023;14:20406207231154713.","journal-title":"Ther Adv Hematol"},{"key":"2639_CR12","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol. 2021;39:1650\u20139.","journal-title":"J Clin Oncol"},{"key":"2639_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41409-024-02363-7","volume":"59","author":"J Ahn","year":"2024","unstructured":"Ahn J, Yoon J-H, Kwag D, Min GJ, Park S-S, Park S, et al. Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2024;59:1413\u201322.","journal-title":"Bone Marrow Transplant"},{"key":"2639_CR14","first-page":"204062072210767","volume":"13","author":"J-H Yoon","year":"2022","unstructured":"Yoon J-H, Min GJ, Park S-S, Park S, Lee S-E, Cho B-S, et al. Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality. Therapeutic Adv Hematol. 2022;13:204062072210767.","journal-title":"Therapeutic Adv Hematol"},{"key":"2639_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41409-020-01097-6","volume":"56","author":"J-H Yoon","year":"2021","unstructured":"Yoon J-H, Min GJ, Park S-S, Park S, Lee S-E, Cho B-S, et al. Impact of donor type on long-term graft-versus-host disease-free\/relapse-free survival for adult acute lymphoblastic leukemia in first remission. Bone Marrow Transplant. 2021;56:828\u201340.","journal-title":"Bone Marrow Transplant"},{"key":"2639_CR16","unstructured":"Network NCC The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Lymphoblastic Leukemia V.3.2024. \u00a9. 2024. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf Accessed 2024 1 December."},{"key":"2639_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2639_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transpl. 2015;21:389\u2013401.e381.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2639_CR19","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333\u20138.","journal-title":"Blood"},{"key":"2639_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cca.2018.10.037","volume":"488","author":"I Jo","year":"2019","unstructured":"Jo I, Chung NG, Lee S, Kwon A, Kim J, Choi H, et al. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia. Clin Chim Acta. 2019;488:81\u201389.","journal-title":"Clin Chim Acta"},{"key":"2639_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.16207","volume":"188","author":"H Rafei","year":"2020","unstructured":"Rafei H, Kantarjian HM, Jabbour EJ. Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. Br J Haematol. 2020;188:207\u201323.","journal-title":"Br J Haematol"},{"key":"2639_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/ejh.13947","volume":"110","author":"C Ferra Coll","year":"2023","unstructured":"Ferra Coll C, Morgades De La Fe M, Prieto Garc\u00eda L, Vaz CP, Heras Fernando MI, Bailen Almorox R, et al. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. Eur J Haematol. 2023;110:659\u201368.","journal-title":"Eur J Haematol"},{"key":"2639_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.HS9.0000843344.19780.98","volume":"6","author":"S Rives","year":"2022","unstructured":"Rives S, Maude SL, Hiramatsu H, Baruchel A, Bader P, Bittencourt H, et al. S112: Tisagenlecleucel in pediatric and young adult patients (Pts) With Relapsed\/Refractory (R\/R) B-Cell Acute Lymphoblastic Leukemia (B-All): Final Analyses From The Eliana Study. HemaSphere. 2022;6:13\u201314.","journal-title":"HemaSphere"},{"key":"2639_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood.2023022330","volume":"143","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, et al. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024;143:417\u201321.","journal-title":"Blood"},{"key":"2639_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231201454","volume":"14","author":"HM Kantarjian","year":"2023","unstructured":"Kantarjian HM, Logan AC, Zaman F, G\u00f6kbuget N, Bargou RC, Zeng Y, et al. Survival outcomes in patients with relapsed\/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab. Ther Adv Hematol. 2023;14:20406207231201454.","journal-title":"Ther Adv Hematol"},{"key":"2639_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11899-022-00664-6","volume":"17","author":"E Pierce","year":"2022","unstructured":"Pierce E, Mautner B, Mort J, Blewett A, Morris A, Keng M, et al. MRD in ALL: Optimization and Innovations. Curr Hematol Malig Rep. 2022;17:69\u201381.","journal-title":"Curr Hematol Malig Rep"},{"key":"2639_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood.2021012412","volume":"141","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Chen Y-B. How I treat with maintenance therapy after allogeneic HCT. Blood. 2023;141:39\u201348.","journal-title":"Blood"},{"key":"2639_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5045\/br.2022.2020305","volume":"57","author":"CCK Liam","year":"2022","unstructured":"Liam CCK, Boo YL, Chong SL, Sathar J, Ong TC, Tan SM. Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease. Blood Res. 2022;57:158\u201361.","journal-title":"Blood Res"},{"key":"2639_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/10428194.2020.1844198","volume":"62","author":"MA Couturier","year":"2021","unstructured":"Couturier MA, Thomas X, Raffoux E, Huguet F, Berthon C, Simand C, et al. Blinatumomab\u2009+\u2009ponatinib for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Leuk Lymphoma. 2021;62:620\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2639_CR30","doi-asserted-by":"publisher","first-page":"398868","DOI":"10.1200\/JCO.2023.41.36_suppl.398868","volume":"41","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gomez-Almaguer D, et al. First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). J Clin Oncol. 2023;41:398868\u2013398868.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02639-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02639-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02639-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:05:56Z","timestamp":1757189156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02639-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2639"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02639-6","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of The Catholic University of Korea (KC25RISI0006) and all methods were conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}